Intervention not reported
Acceptability of treatment: Leaving the study early · patients with antipsychotic‐induced TD
It is very uncertain whether the intervention changes acceptability of treatment: Leaving the study early (very low certainty).
1 finding from 1 review
Secondary outcome: acceptability of treatment · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether CHOLINERGIC DRUGS changes acceptability of treatment: Leaving the study early compared with PLACEBO (very low certainty).
1 finding from 1 review
Secondary outcome: acceptability of treatment · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Secondary outcome: acceptability of treatment · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether DOPAMINERGIC DRUGS changes acceptability of treatment: Leaving the study early compared with PLACEBO (very low certainty).
1 finding from 1 review
Secondary outcome: acceptability of treatment · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether DOPAMINERGIC DRUGS changes acceptability of treatment: Leaving the study early compared with OTHER DRUGS (very low certainty).
1 finding from 1 review
Secondary outcome: acceptability of treatment · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether NORADRENERGIC DRUGS changes acceptability of treatment: Leaving the study early compared with PLACEBO (very low certainty).
1 finding from 1 review
Intervention not reported
Acceptability of treatment ‐ leaving the study early · people with antipsychotic‐induced tardive dyskinesia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Leaving the study early · chronic schizophrenia patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether anticholinergic medication changes acceptability of the treatment: leaving the study early compared with other treatments (very low certainty).
1 finding from 1 review
Leaving the study early · chronic schizophrenia patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether withdrawal of anticholinergic medication changes acceptability of the treatment: leaving the study early compared with continuing anticholinergic medication (very low certainty).
1 finding from 1 review
Leaving the study early · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Leaving the study early · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether switch to another antipsychotic changes acceptability of the treatment: leaving the study early compared with antipsychotic cessation (very low certainty).
1 finding from 1 review
Leaving the study early · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Leaving the study early · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether specific antipsychotic changes acceptability of the treatment: leaving the study early compared with other drugs (very low certainty).
1 finding from 1 review
Leaving the study early · female and male 42 (mean) years old patients with schizophrenia or schizoaffective disorder and antipsychotic‐induced tardive dyskinesia
It is very uncertain whether reduced dose of antipsychotics changes acceptability of the treatment: leaving the study early compared with antipsychotic maintenance (very low certainty).
1 finding from 1 review
RR 0.33 [0.06, 1.99]
1 study · 8 participants
Very low
Leaving the study early · patients with schizophrenia
It is very uncertain whether adjunctive carbamazepine + antipsychotics changes acceptability of treatment Leaving the study early due to any reason compared with placebo/no adjunctive treatment + antipsychotics (very low certainty).
1 finding from 1 review
Leaving the study early · patients with schizophrenia
It is very uncertain whether perazine changes acceptability of treatment Leaving the study early due to any reason compared with placebo (very low certainty).
1 finding from 1 review
Acceptability of treatment ‐ leaving the study early · patients with schizophrenia
FLUPHENAZINE showed no clear difference in acceptability of treatment‐leaving the study early due to any reason compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (moderate certainty).
1 finding from 1 review
Satisfaction with treatment: leaving the study early Endpoint data (events) · people with treatment‐resistant schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Satisfaction with treatment: leaving the study early Endpoint data (events) · people with treatment‐resistant schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Satisfaction with treatment: leaving the study early Endpoint data (events) · people with treatment‐resistant schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found